Ticker

Allianz Asset Management GmbH boosted its position in shares of Adaptive Biotechnologies Corporation (NASDAQ: ADPT) by 305.8% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 321,774 shares of the company's stock after acquiring an additional 242,474 shares during the quarter. Allianz Asset

Adaptive Biotechnologies Corporation (ADPT) Q4 2025 Earnings Call Transcript

Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) CEO Chad Robins sold 124,998 shares of the business's stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $18.44, for a total value of $2,304,963.12. Following the completion of the sale, the chief executive officer directly owned 2,459,245 shares

While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.23 per share a year ago.